[Molecular Target Therapy for Soft Tissue Sarcoma]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Soft tissue sarcoma (STS) represents a group of rare and challenging malignancies.
• Most STS subtypes exhibit resistance to conventional chemotherapy, necessitating novel therapeutic strategies.
• Specific chromosomal translocations are observed in 20-30% of STS cases, yielding transcriptional factors that are difficult to target directly.

Purpose of the Study:

• To review the current landscape of targeted therapies for soft tissue sarcomas.
• To highlight the challenges and advancements in developing molecularly targeted treatments for STS.
• To discuss the efficacy of existing and emerging therapeutic agents, including Trabectedin, angiogenesis inhibitors, and immune checkpoint inhibitors.

Main Methods:

• Literature review of studies on soft tissue sarcoma treatment.
• Analysis of therapeutic strategies targeting chromosomal translocations and gene mutations in STS.
• Evaluation of the role of angiogenesis inhibitors and immune checkpoint inhibitors in STS management.

Main Results:

• Trabectedin demonstrates efficacy in translocation-related sarcomas (TRS) by alkylating DNA and inhibiting transcriptional factors.
• Targeted therapies for gene mutations (e.g., c-kit, PDGFR) have shown success in specific rare sarcomas like GIST, IMT, and DFSP.
• Angiogenesis inhibitors (e.g., pazopanib) and immune checkpoint inhibitors are emerging as potential treatments for STS.

Conclusions:

• Development of specific molecular targeted therapies tailored to individual STS subtypes is essential.
• Trabectedin offers a treatment option for translocation-related sarcomas.
• Further research into angiogenesis inhibition and immunotherapy holds promise for advancing STS treatment.